ARK Invest Pivots: Cathie Wood Exits Twist Bioscience for Circle Internet

ARK Invest, led by the high-profile fund manager Cathie Wood, has once again signaled a shift in its investment thesis by divesting from the synthetic biology sector to double down on digital asset infrastructure. The recent trades, which saw ARK offloading a significant portion of its holdings in Twist Bioscience (TWST) while acquiring shares in Circle Internet (CRCL), highlight a strategic rotation within the firm’s flagship disruptive innovation portfolios. This move comes at a critical juncture for both companies, as the biotechnology sector faces headwinds from high interest rates while the digital finance ecosystem prepares for a new wave of institutional adoption.

Twist Bioscience has long been a staple in ARK’s genomic revolution strategy. The company, which utilizes a proprietary silicon-based platform to "write" DNA, has been positioned as a fundamental layer for the future of personalized medicine, data storage, and sustainable chemicals. However, the capital-intensive nature of the synthetic biology industry has made it sensitive to the broader market's appetite for risk. By trimming its position in Twist, ARK may be reacting to a perceived plateau in the company’s near-term growth trajectory or simply reallocating capital toward opportunities with more immediate catalysts. The synthetic biology market has seen increased competition, and while Twist remains a leader, its path to profitability has been a point of contention for some institutional investors.

“

ARK Invest, led by the high-profile fund manager Cathie Wood, has once again signaled a shift in its investment thesis by divesting from the synthetic biology sector to double down on digital asset infrastructure.

In contrast, the move into Circle Internet represents a high-conviction bet on the "plumbing" of the digital economy. Circle is the issuer of USDC, a stablecoin that has positioned itself as the regulated, transparent alternative to Tether (USDT). For ARK, Circle is not just a crypto play; it is a play on the future of global payments and settlements. As Circle moves closer to its anticipated public listing, ARK’s entry or expansion in the stock suggests a belief that the company’s revenue model—which generates significant income from interest on the dollar reserves backing USDC—is uniquely positioned to thrive even if broader crypto volatility persists. This revenue stream has become a major driver for Circle, especially in a sustained higher-for-longer interest rate environment.

This portfolio rebalancing also reflects a broader trend in Cathie Wood’s management style: the concentration of capital into "highest conviction" names during periods of market uncertainty. While Twist Bioscience remains a leader in its niche, the competitive landscape in genomics is becoming increasingly crowded with both legacy players and well-funded startups. Meanwhile, Circle’s dominant position in the regulated stablecoin market provides a moat that is difficult for competitors to replicate, especially as global regulators move toward clearer frameworks for digital assets. The shift underscores a preference for infrastructure-level plays that can capture value across an entire ecosystem rather than single-product biotech firms.